文献速递间质性肺疾病

间质性肺病定量影像特征对自身免疫性ILD免疫调节治疗反应的影响

Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohorts.
PubMed 文献 · Thorax · 2025-07-15

本研究利用三个自身免疫性间质性肺病队列(两个系统性硬化症队列和一个类风湿关节炎队列),采用线性回归分析基线定量磨玻璃影、纤维化及其比值与12个月免疫调节治疗后FVC%预计值变化的关系。结果显示,GGO与纤维化比值增高与FVC%改善无关;但在接受环磷酰胺治疗的SSc-ILD患者中,纤维化和GGO程度增加均与FVC%改善显著相关。

要点

  • GGO与纤维化比值增高未显示与免疫调节治疗后的FVC%改善相关。
  • 在SSc-ILD接受环磷酰胺治疗者中,纤维化及GGO程度增加与FVC%改善相关。
  • 霉酚酸酯治疗的SSc-ILD及RA-ILD患者中未见显著相关性。

核心结论

  • 定量GGO相对纤维化增加与RA-ILD和SSc-ILD患者免疫调节治疗反应改善无显著相关。
  • 在SSc-ILD中,纤维化和GGO程度增加与环磷酰胺治疗后的FVC%改善相关。

研究设计与样本

  • 研究利用三个自身免疫性ILD队列:两个系统性硬化症队列和一个类风湿关节炎队列。
  • 采用线性回归模型分析基线定量GGO、纤维化及其比值与12个月免疫调节治疗后FVC%预计值变化的关系。

主要发现

  • SSc-ILD患者(N=262)的GGO与纤维化比值高于RA-ILD患者(N=130),平均比值分别为3.0和0.25。
  • 在任何队列中,GGO与纤维化比值增加均与FVC%预计值改善无关。
  • 在接受环磷酰胺治疗的SSc-ILD患者中,纤维化增加(估计值0.17,95%CI 0.003-0.33;p=0.04)和GGO增加(估计值0.15,95%CI 0.004-0.30;p=0.044)均与FVC%改善显著相关。
  • GGO与纤维化比值的估计值为负(估计值-0.33,95%CI -0.61至-0.06;p=0.016),提示纤维化相对GGO程度更高的患者接受环磷酰胺后FVC%改善更明显。
  • 在接受霉酚酸酯治疗的SSc-ILD患者(N=56)或接受免疫调节治疗的RA-ILD患者(N=130)中未见显著相关性。

临床怎么用

  • 对于SSc-ILD患者,基线定量影像显示的纤维化和GGO程度可能有助于评估环磷酰胺治疗后的肺功能改善可能性。
  • GGO与纤维化比值不宜作为RA-ILD或SSc-ILD患者免疫调节治疗反应的预测指标。

局限性

  • 需要更多研究来理解如何利用影像学特征指导ILD的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The defining radiological features of autoimmune interstitial lung disease (ILD) are ground glass opacification (GGO) and fibrosis. The associations between these features and physiological response to immunomodulation remain unclear. METHODS: This study leveraged three autoimmune ILD cohorts: two with systemic sclerosis (SSc) and one with rheumatoid arthritis (RA) which were selected for inherent differences in fibrotic extents/patterns. Linear regression models examined associations between baseline quantitative GGO, fibrosis, their ratio and forced vital capacity (FVC)%-predicted changes after 12 months of immunomodulatory therapy. RESULTS: Patients with SSc-ILD (N=262) exhibited a higher GGO-to-fibrosis ratio compared with patients with RA-ILD (N=130) (mean ratio 3.0 vs 0.25). Increased GGO-to-fibrosis was not associated with improved FVC%-predicted in any cohort. Conversely, in patients with SSc-ILD treated with cyclophosphamide (CYC), increased fibrosis (estimate 0.17 (95% CI 0.003, 0.33); p=0.04) and increased GGO (estimate 0.15 (95% CI 0.004, 0.30); p=0.044) were both significantly associated with FVC% improvement. Given the negative direction of the estimate for GGO-to-fibrosis ratio (estimate -0.33 (95% CI -0.61, -0.06); p=0.016), CYC was associated with greater FVC% improvement in patients with a higher degree of fibrosis relative to GGO. No significant correlation was seen in patients with SSc-ILD treated with mycophenolate (N=56) or in patients with RA-ILD treated with immunomodulation (N=130). DISCUSSION: Increased quantitative GGO relative to fibrosis was not significantly associated with improved response to immunomodulation in patients with RA-ILD and SSc-ILD. However, increased quantitative fibrosis and GGO extent were associated with improved response to CYC in SSc-ILD. More research is needed to understand how to use radiological features to guide treatment selection in ILD.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Matson SM, Kim GHJ, Humphries SM, et al. Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohorts. Thorax. 2025. PMID: 40210443. doi:10.1136/thorax-2024-222367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。